MYC is a master transcriptional regulator that controls almost all cellular processes. Over the
last several decades, researchers have strived to define the context-dependent …

Acute promyelocytic leukemia (APL) is a rare disease accounting for only 5%–10% of
pediatric acute myeloid leukemia (AML) and fewer than 1000 cases occur annually in the …

Given that triple-negative breast cancer (TNBC) lacks specific receptors (estrogen and
progesterone receptors and human epidermal growth factor receptor 2) and cannot be …

Background: Over the past four decades, outcomes for osteosarcoma patients have
plateaued as there have been few emerging therapies showing clinical results. Thus, the …

Hybrid nanomaterials with unique physiochemical properties have received a lot of
attention, making them attractive for application in different fields like cancer treatment. This …

Overexpression of c-Myc plays an essential role in leukemogenesis and drug resistance,
making c-Myc an attractive target for cancer therapy. However, targeting c-Myc directly is …

Immunotherapy using antibodies blocking the programmed cell death 1 (PD-1)/programmed
cell death-ligand 1 (PD-L1) pathway has achieved great success in preclinical models and …

Drug resistance is currently one of the biggest challenges in cancer treatment. With the
deepening understanding of drug resistance, various mechanisms have been revealed …

Patients who sustain a traumatic brain injury (TBI) are known to have a significantly quicker
fracture healing time than patients with isolated fractures, but the underlying mechanism has …

Despite an old history behind the identification of the leading role of c‐Myc in
leukemogenesis, the road to constructing a therapeutic perspective for this molecule in …